Market Intelligence is crucial to risk reduction in the API supplier regulatory filing process. Market Intelligence is even more important for risk mitigation during the API supplier regulatory filing process.
The pharmaceutical market is arguably the most regulated of all the markets across the globe. For pharmaceutical manufacturers, the choice of an Active Pharmaceutical Ingredient (API) supplier goes beyond mere procurement, and is more about the management of risk.Examples of an API supplier's regulatory non-compliance risks include: delays in product approvals, supply chain interruptions, product recalls, import alerts, and financial impacts.
Market intelligence is being used by companies to reduce the risk of evaluating suppliers more effectively, as global pharmaceutical supply chains become more complex. A comprehensive, trusted global API supplier list and regulatory intelligence help procurement and regulatory teams find potential problems before they happen—and at a lower cost.
Market intelligence is a critical solution in today's pharmaceutical competitive environment to minimize regulatory risk due to API supplier selection and qualification.
Regulatory filings are helpful tools to discover the compliance and credibility of an API manufacturer. These submissions are a demonstration that a supplier meets the quality and regulatory standards set by health authorities around the world.
The most significant regulatory papers are:
Pharmaceutical companies tend to focus on cost or production capacity when they are considering the supplier, while they neglect the significant regulatory criteria that can affect supply continuity.
An API supplier may have a long history of regulatory violations despite having competitive pricing, or may have inactive DMFs and/or unaddressed inspection observations.For instance, an API supplier might have a track record of regulatory infractions even though the prices they offer are competitive, or they may not have active DMFs and/or unaddressed inspection observations.
Utilizing regulatory filings in supplier qualification can lead to better sourcing decisions and mitigation of compliance risks.
Many pharmaceutical companies tend to purchase APIs from various countries to cut costs and increase their supply chain diversity. This is a benefit, but it also comes with new challenges.
One global API supplier could have a manufacturing plant in various regions with different regulations. Without centralized intelligence, it can get cumbersome to monitor compliance efforts in multiple suppliers, products, and geographies.
Typical supplier-related regulatory risks encompass:
These risks may impact product development schedule, regulatory submissions, and commercialization.
That implies the need for procurement and regulatory groups to see the supplier compliance performance across the supplier lifecycle.
Market intelligence is the collection, analysis and monitoring of data that is critical to strategic business decision making.
Market intelligence in pharmaceutical sourcing is a fusion of data from several sources, such as:
Companies can use dynamic intelligence platforms that enable ongoing supplier performance and compliance monitoring, instead of depending on static supplier directories.
A complete API suppliers list around the globe with market intelligence can help companies compare suppliers according to both commercial standards and regulation.
This way, supplier qualification is no longer a process of reacting but rather an act of risk management.
The best advantage of market intelligence is to identify warning indicators before going into supplier contracts.
Regulatory intelligence helps procurements teams evaluate:
The governments have taken decisions to regulate in the interest of health (e.g., banning smoking in public areas).
The sooner an organisation identifies the problems with suppliers, the sooner it will not have problems to deal with down the road.
Drug Master Files are an integral part of API supplier evaluation.
An active DMF indicates a supplier's documentation and customer submission support. But because of inactivity, changes in ownership, or regulatory shortcomings, however, the status of DMF can change over time.
Market intelligence platforms can assist companies in tracking:
With continuous monitoring, procurement staff can ensure that they will be working with suppliers who have current regulatory paperwork.
Supplier compliance is a case-by-case basis scenario. What is successful for a supplier in the present, may not be successful in the future.
Organizations can monitor through market intelligence:
This continual visibility will help organisations to be more agile to any changes in threat and to have plans ready should they be required.
There are still a number of API suppliers for many pharmaceutical companies that rely on them heavily.
If there's a problem with a supplier, this concentration can be a risk.
Market intelligence provides a more extensive set of API suppliers for the procurement team to choose from when finding qualified alternative suppliers.
Supplier diversification helps to lessen reliance on single source suppliers and enhances supply chain resilience.
Traditional supplier qualification is based on questionnaires, audits and document review.
These are still vital but only show a sample of supplier quality.
Market intelligence provides an additional level of validation by providing:
Internal audits and external intelligence result in better supplier qualification decisions.
Minimising risk from regulators demands more than just an ad hoc supplier audit. Companies must have a systematic supplier risk management strategy.
A contemporary supplier risk architecture ought to consist of:
Use a detailed API supplier list that offers verified supplier data, manufacturing capabilities, and regulatory listings across the globe to locate qualified manufacturers.
Assess supplier filings, certifications, inspection history and compliance records prior to starting qualification activities.
Use risk scores that are derived from the following:
There is no reason why supplier compliance should be monitored only onboarding, as it should be throughout the relationship.
Constant surveillance can lead to businesses realizing their risk profiles have shifted and taking action in advance.
Keep backup suppliers and dual sourcing to minimise impact on regulatory disruption.
Organizations which have adopted these practices are better primed to deal with compliance dangers and ensure business continuity.
Regulatory departments are increasingly collaborating with procurement & supply chain teams to assess suitability.
Market intelligence generates a common source of truth by delivering access to:
This partnership enhances the decisions made by several functions.
Teams can assess suppliers with all the information they need to evaluate compliance and commercial goals in a single intelligence source rather than information from many different sources.
The outcome is quicker supplier qualification, less risk of regulatory issues and better sourcing results.
As the pharmaceutical supply chains have grown and expanded across the globe, it is becoming harder to find the right supplier.
A reliable global API supplier list offers more than just contact details. It's a strategic asset for:
Access to trusted supplier intelligence will also help organisations find qualified suppliers more efficiently and minimise risk of expensive compliance issues.
Supplier databases can be used to create more effective sourcing decisions and boost supply chain resiliency when used alongside regulatory intelligence and market insights.
Accurate & real-time supplier intelligence is crucial for pharmaceutical procurement, sourcing and regulatory teams.
Organizations can access Chemxpert Database to help them make informed supplier decisions based on:
Global API suppliers lists are available.Global API supplier lists exist.
Chemxpert integrates key supplier, product, and regulatory information into a single platform to better assess suppliers, and better uncover potential risks before they affect operations.
This intelligence-led approach helps to drive better supplier qualification, compliance regulation, and more robust pharmaceutical supply chains.
Regulatory compliance is no longer a "nice to have" in the selection of suppliers in today's pharmaceutical industry. This is a key element that has a direct impact on product quality, access to the market and business continuity.
Market intelligence gives pharmaceutical companies the information needed to get beyond the traditional supplier assessment and take a proactive stance in risk management. This enables organisations to minimise compliance risks early, improve supplier qualifying, and create more resilient supply chains by using data from the regulators, supplier intelligence and a comprehensive list of API suppliers worldwide.
In an ever-changing regulatory landscape, companies that adopt intelligence-based sourcing practices will have a better chance of managing risk, supplier performance, and staying competitive in the global pharmaceutical scene.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!